Besides offering commercial services, SciBerg is actively participating in both fundamental and applied research projects together with other academic and industrial partners. Our primary interests are focused on the investigation of cell-free circulating RNA and DNA in human biofluids, the exploration of their potential for early non-invasive diagnosis of multiple human disorders and the development of novel approaches for data analysis. The peer-reviewed publications resulting from the non-profit scientific activity of our company are listed below.
Turchinovich A, Drapkina O and Tonevitsky A. Transcriptome of Extracellular Vesicles: State-of-the-Art // Frontiers in Immunology (2019), 10:202.
Extracellular membrane vesicles are released by almost all cell types and are highly abundant in biological fluids. Importanly, RNA cargo within extracellular vesicles hold tremendous potential as non-invasive biomarkers for multiple disorders, including pathologies of the immune system. This mini-review is aimed to provide the state-of-the-art in the field of extracellular vesicles-associated RNA transcriptome, as well as the comprehensive analysis of previous studies characterizing RNA content within vesicles released by various cells using next-generation sequencing. We also highlight the technical challenges associated with obtaining pure extracellular membrane vesicles or certain type and deep sequencing of their RNA cargo.
Turchinovich A, Baranova A, Drapkina O and Tonevitsky A. Cell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated Disorders // Frontiers in Physiology (2018), 9:1256.
Normally, intracellular miRNAs participate in the regulation of gene expression, but once released by dying/dead cells they remain highly stable in the extracellular environment for prolonged periods. Therefore, circulating miRNA profiles can reflect the ongoing pathogenic processes in the body’s tissues and organs, and enable highly sensitive non-invasive diagnosis of multiple disorders. This review article summarizes the state-of-the-art in the field of early diagnosis of non-alcoholic fatty liver disease (NAFLD) using extracellular circulating RNAs. It also emphasizes on the practical utility of circulating miRNAs as biomarkers for longitudinal monitoring of human health.
Galatenko VV, Galatenko AV, Samatov TR, Turchinovich AA, Shkurnikov MY, Makarova JA and Tonevitsky AG. Comprehensive network of miRNA-induced intergenic interactions and a biological role of its core in cancer // Scientific Reports (2018), 8:2418.
This study addressed the analysis of the entire network of gene-gene interactions mediated by intragenic miRNAs and identified the network core consisting of genes mutually connected via their intragenic miRNAs. Interestingly, genes forming the core were involved in key cellular processes, including DNA replication, transcription, protein homeostasis and cell metabolism. The described network core, consisting of genes mutually regulated by their intragenic miRNAs, could coordinate adjacent pathways or homeostatic control circuits, serving as a horizontal inter-circuit link. Notably, expression patterns of these genes had an efficient prognostic potential for breast and colorectal cancer patients.
Sartorius K, Sartorius B, Kramvis A, Singh E, Turchinovich A, Burwinkel B, Madiba B and Winkler CA. Circulating microRNA’s as a diagnostic tool for hepatocellular carcinoma in a hyper endemic HIV setting, KwaZulu-Natal, South Africa: a case control study protocol focusing on viral etiology // BMC Cancer (2018), 17:894.
This article describes the experimental design and the protocol for the upcoming study to be conducted by several collaboration partners, including German Cancer Research Center, University of the Witwatersrand (South Africa), National Cancer Institute (USA) and SciBerg e.Kfm. The aims of this proposed study is the identification of circulating miRNAs biomarkers for hepatocellular carcinoma (HCC) in a setting with high HIV/HBV co-infection. We foresee that HCC specific blood-based miRNA biomarkers will be useful for early diagnosing of HCC as well as predicting the clinical course and/or therapeutic response to chemotherapy.
Legal form: Sole Proprietorship
Birkenauer Str. 7, Mannheim 68309, Germany
Amtsgericht Mannheim HRA 707401
VAT identification number: DE 312303132
Phone: +49 171 190 8276